Molnupiravir-EIDD-2801-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEMolnupiravirCat.No.:HY-135853CASNo.:2492423-29-5Synonyms:EIDD-2801;MK-4482分?式:C??H??N?O?分?量:329.31作?靶點(diǎn):SARS-CoV;InfluenzaVirus作?通路:Anti-infection儲存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:50mg/mL(151.83mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲備液1mM3.0367mL15.1833mL30.3665mL5mM0.6073mL3.0367mL6.0733mL10mM0.3037mL1.5183mL3.0367mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；?旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲存時，請?jiān)?個?內(nèi)使?，-20°C儲存時，請?jiān)?個?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請根據(jù)您的實(shí)驗(yàn)動物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請先按照InVitro?式配制澄的儲備液，再依次添加助溶劑：(為保證實(shí)驗(yàn)結(jié)果的可靠性，澄的儲備液可以根據(jù)儲存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1.請依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%saline1/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemESolubility:≥2.5mg/mL(7.59mM);Clearsolution2.請依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥2.5mg/mL(7.59mM);Clearsolution3.請依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥2.5mg/mL(7.59mM);Clearsolution4.請依序添加每種溶劑：10%PEG400>>2.5%Ethoxylatedhydrogenatedcastoroil>>87.5%waterSolubility:12.05mg/mL(36.59mM);Clearsolution;NeedultrasonicBIOLOGICALACTIVITY?物活性Molnupiravir(EIDD-2801)核糖核苷類似物EIDD-1931的?服?物可利?的異丙酯前藥。Molnupiravir顯?出?泛的抗流感病毒(influenzavirus)和冠狀病毒(coronaviruses)的活性，如SARS-CoV-2，MERS-CoV，SARS-CoV。Molnupiravir有?于COVID-19和季節(jié)性，流?性流感的潛?。體內(nèi)研究Molnupiravir(50-500mg/kg;p.o.;every12hoursfor3days)isrobustlyantiviralandabletopreventSARS-CoVreplicationanddisease[1].Molnupiravir(7mg/kg;p.o.;twicedailyfor3.5days)significantlyreducesshedvirusloadanddurationoffever[2].AnimalModel:C57BL/6mice(intranasalinfectionwithSARS-CoV)[1]Dosage:50,150,500mg/kgAdministration:Oral;every12hoursfor3daysResult:Bodyweightlossissignificantlydiminishedorprevented.AnimalModel:Ca/09-infectedfemaleferrets[1]Dosage:7mg/kgAdministration:Oral;twicedailyfor3.5daysResult:Shedvirusloadanddurationoffeverweresignificantlyreduced.戶使?本產(chǎn)品發(fā)表的科研?獻(xiàn)?Nature.2022Apr;604(7904):134-140.?Cell.2022Nov10;185(23):4347-4360.e17.?NatMicrobiol.2022Jun15.?NucleicAcidsRes.2021Jan8;49(D1):D1113-D1121.?NatCommun.2021Nov5;12(1):6415.Seemorecustomervalidationsonwww.MedChemE2/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemEREFERENCES[1].TootsM,etal.Characterizationoforallyefficaciousinfluenzadrugwithhighresistancebarrierinferretsandhumanairwayepithelia.SciTranslMed.2019Oct23;11(515).pii:eaax5866.[2].SheahanTP,etal.Anorallybioavailablebroad-spectrumantiviralinhibitsSARS-CoV-2inhumanairwayepithelialcellculturesandmultiplecoronavirusesinmice.SciTranslMed.2020Apr6.pii:eabb5883.McePdfHeightCaution:Producthasnotbeenfullyvalidatedfor